ライフサイエンスコーパス: personalized

1 nts are "one-size fits-all" instead of being personalized.

2 .7 GBq at Gustave Roussy (GR, n = 231) or by personalized activity (2.7-18.6 GBq) based on whole-body

3 onses; we used this information to develop a personalized, activity-based normalization framework to

4 a mechanistic model, to generate real-time, personalized, adaptable glucose forecasts; (ii) model av

5 iple-assignment randomized trials to develop personalized adaptive treatment strategies (ATSs)-longit

6 d fears about treatment, before developing a personalized adherence strategy.

7 omises to help us achieve a more precise and personalized allocation of therapy for our cardiovascula

8 A personalized analysis of risk factors could be used to m

9 The KF can generate personalized and dynamically updated forecasts of OAG pr

10 e and hand-held body fat burn monitoring for personalized and immediate feedback on workout effective

11 , triage, and therapy for patients in a more personalized and precise manner.

12 g, disease monitoring, drug development, and personalized and precision medicine for lymphoma are dis

13 ychiatry paralleling similar developments in personalized and precision medicine.

14 rovide a neuroscience-informed framework for personalized and public health interventions to promote

15 The emergence of personalized and stratified medicine requires label-free

16 findings of the Care Ecosystem, an adaptive, personalized, and scalable dementia care program.

17 , respectively, from the use of OCT to guide personalized anti-VEGF treatment.

18 ge needed to advance a precision approach to personalized antidepressant choices.

19 Endotype-driven treatment is part of a personalized approach and should be positioned at the te

20 This non-invasive and personalized approach can synthesize medical data into c

21 rms cannot be manufactured rapidly or when a personalized approach is required.

22 Such a personalized approach may be more sensitive to gender di

23 onic obstructive pulmonary disease (COPD), a personalized approach to care.

24 OSA lends itself to a personalized approach to diagnosis and therapy.

25 erapeutic implications and lend support to a personalized approach to NSCLC management based on molec

26 We also studied a more personalized approach, by psychiatric diagnosis and gend

27 an urgent need to treat breast cancer with a personalized approach.

28 al-trial evidence that supports PET-directed personalized approaches in lymphoma.

29 and diagnosis, and show that the subtype and personalized approaches permit enhanced precision of pre

30 tively normalize the dysbiotic microbiome in personalized approaches to treatment.

31 a computer-assisted assessment determining a personalized array of intervention modules and subsequen

32 Such a relationship suggests that personalized assessment of suitability of BCI as a commu

33 vely, these results allow for a detailed and personalized assessment of the patient immune response t

34 MI exist that may warrant considering SMI in personalized assessments of coronary heart disease risk.

35 in the course of treatment could facilitate personalized assignment to treatment.

36 ry and investigated it as a means to support personalized assistance and therapy within the home envi

37 de a blueprint for the future development of personalized, autologous anticancer vaccines with broad

38 es in body mass index (BMI), (iv) used these personalized avatars as stimuli to allow the women to es

39 Infants also receive distinct, personalized, bacterial exposures leading to differentia

40 everybody versus testing by subtypes versus personalized by gender and diagnosis, and show that the

41 and other delivery systems for targeted and personalized cancer chemotherapy.

42 berrant splicing, which can be exploited for personalized cancer immunotherapy.

43 he potential of proteome profiling to inform personalized cancer medicine.

44 e novel insights to combination therapies in personalized cancer medicine.

45 and therapeutic modalities for improved and personalized cancer theranostics in the future.

46 tion to discover new opportunities to refine personalized cancer therapies.

47 tion for discovering opportunities to refine personalized cancer therapies.Significance: Systematic a

48 The development of personalized cancer therapy depends on a robust system t

49 Personalized cancer therapy seeks to tailor treatment to

50 The Personalized Cancer Therapy website (www.personalizedcan

51 dividual tumors provides great potential for personalized cancer therapy.

52 ivation, with implications for improving the personalized care and survival outcomes of ovarian cance

53 sting, guide targeted therapies, and advance personalized care for patients with CRC.

54 y help guide clinical evaluations to improve personalized care in limiting neurotoxicity in cancer su

55 The combination of personalized care, prediction of treatment success, prev

56 ortunities for in vitro disease modeling and personalized cell replacement therapy.

57 tem cells (iPSCs) are ideal cell sources for personalized cell therapies since they can be expanded t

58 surements for up to 43 individuals, we found personalized circadian differences in physiological para

59 ring ApoE epsilon3/epsilon4, and brings into personalized clinical practice the immune benefits expec

60 emphasize the need to address challenges in personalized communication about genetic testing.

61 Personalized computational models that can accurately fo

62 On the basis of personalized cytogenetic profiles, Kaplan-Meier estimate

63 -related metastasis strongly correlates with personalized cytogenetic profiles, with 5-year Kaplan-Me

64 nsideration of gut microbial composition for personalized diet recommendations.

65 that individuals with MetS may benefit from personalized dietary interventions based on APOE genotyp

66 uding induced PSCs, hold great potential for personalized disease modeling, drug testing and cell-bas

67 tients with these diseases and to facilitate personalized disease monitoring and treatment are also a

68 pproach may contribute to the development of personalized dose regimen.

69 ions and has helped match patients with more personalized drugs.

70 Personalized estimates of the change in MD under differe

71 This novel approach to personalized estimation of benefits from risk-reducing t

72 ving kidney donors in the United States, but personalized estimation on the basis of donor characteri

73 great relevance due to its potential role in personalized exercise medicine applications.

74 plementary foods until 6 months of age and 3 personalized face-to-face contacts (at 5.5, 7.0, and 9.0

75 nation campaigns) and when they get the flu (personalized flu warnings) could have a large impact on

76 ike many immunotherapies does not need to be personalized for each patient.

77 To generate personalized forecasts of how patients with open-angle g

78 clinical decision-making tool that generates personalized forecasts of the trajectory of OAG progress

79 nalized group (level 0) but not in the other personalized groups (level 1 and 2).

80 Personalized health care (PHC) is being appreciated glob

81 le electronics have the potential to advance personalized health care, alleviate disability, enhance

82 PHC includes personalized health monitoring (PHM), which is its integ

83 eted bioactive platforms for next-generation personalized healthcare technologies.

84 in wearable electronics, home security, and personalized healthcare.

85 contractility was inversely determined from personalized heart models by matching CMR-imaged LV dyna

86 Personalized heart muscle cells made from stem cells in

87 The development of functional and personalized holographic devices in the visible and near

88 Hence, a simple, personalized, home-based, low-intensity exercise program

89 to exon 1, and for preclinical screening of personalized HTT lowering therapies in HD patients of Ea

90 n intensive 16-week LS intervention program (personalized hypocaloric normoproteic diet and 60 min/wk

91 ngs to the clinical arena will help generate personalized ICBT strategies that target tumor-specific

92 Progress in the new personalized ICBT strategies will expand the reach of im

93 However, the personalized identification and validation of neoantigen

94 we discuss future prospects for integrating personalized immunoengineering with optogenetics to over

95 We used a personalized immunogenomic approach to elucidate the glo

96 This approach could enable personalized immunotherapeutic regimens in patients with

97 ability to other challenging fields, such as personalized immunotherapy against cancer.

98 ome sequencing have signalled the new era of personalized immunotherapy with patient-specific neoanti

99 nic forms of NS, and to efficiently generate personalized in vivo models of genetic renal diseases be

100 ase and likewise would enable development of personalized, in vitro cardiac disease models.

101 There is a great deal of interest in personalized, individualized, or precision interventions

102 trials can be used to assess the utility of personalized interventions and, in addition, can be craf

103 ed, these patterns can inform the search for personalized interventions targeting neurobiological pat

104 provide opportunity for early diagnosis and personalized interventions to mitigate the effect on neu

105 ttings to predict and prevent problems using personalized interventions.

106 and sensitivity would significantly advance personalized liver transplant recipient care and managem

107 mple nomogram based on the ALBI grade offers personalized long-term survival data for patients with e

108 an ultimately bring us closer to the goal of personalized lymphoma care.

109 V/AIDS progression is crucial for developing personalized management and clinical counselling strateg

110 cal outcomes and may be a valuable guide for personalized management and treatment of chronic wounds.

111 eterogeneity needs to be evaluated so that a personalized management approach can be provided.

112 entially providing essential information for personalized management in some patients.

113 nt insights into the role of exosomes in the personalized management of injury and repair responses i

114 ase (MRD) has led to significant advances in personalized management of patients with hematologic mal

115 nable us to predict and prevent disease in a personalized manner.

116 es coherent implementation of treatment in a personalized manner.

117 defined remaining research gaps hindering a personalized medical approach for diabetes to drive the

118 Until now, such personalized medical approaches have largely centered on

119 e emphasis on "big data," phenomenology, and personalized medical therapies.

120 may help in the application of principles of personalized medicine and in decision making for targete

121 vel, which will be an important step towards personalized medicine and infectious disease management.

122 t microbial xenobiotic metabolism will guide personalized medicine and nutrition, inform toxicology r

123 PCa detection is critical to personalized medicine and varies considerably under an M

124 e and raises the possibility of their use in personalized medicine applications.

125 Here we have designed a personalized medicine approach called gene expression an

126 er Genome Atlas database indicated that this personalized medicine approach could also be applied to

127 search with the potential of applications in personalized medicine as well as in drug development.

128 therapy and highlights the possible role for personalized medicine based on deiodinase polymorphisms.

129 tratified according to risk of IA, providing personalized medicine based on strategic evidence for th

130 versity, enabling not just basic research in personalized medicine but also accurate diagnostics and

131 linical outcomes, has the potential to drive personalized medicine by enabling individualized risk st

132 fundamentally change clinical proteomics and personalized medicine by facilitating large-scale studie

133 oth the epithelial and stromal compartments, personalized medicine efforts to integrate molecular inf

134 are globally and opened up new prospects for personalized medicine for the fetus.

135 h is important to consider when implementing personalized medicine in asthmatic patients.

136 programs, and can aid in the development of personalized medicine in humans.

137 h EHRs to predict GDM, which will facilitate personalized medicine in maternal health management in t

138 mice may lead to the implementation of truly personalized medicine in the clinic.

139 otoxicity of tacrine, providing insights for personalized medicine initiatives.

140 search; interdisciplinary work suggests that personalized medicine is on the horizon.

141 It may be that if the goal of personalized medicine is to be realized and biomarkers a

142 Personalized medicine provides a strategic approach to t

143 Using the data from the Marshfield Personalized Medicine Research Project, a site in the el

144 pproach constitutes a potential strategy for personalized medicine that enhances inference from stati

145 The realization of personalized medicine through human induced pluripotent

146 ore their importance for topics ranging from personalized medicine to theories of the evolution of ho

147 ifts, market changes, and patient demand for personalized medicine will require physicians to embrace

148 Because we are now entering the era of personalized medicine, a systems biology approach mergin

149 odels are becoming popular in the context of personalized medicine, but a new study shows that these

150 n recently because of their potential use in personalized medicine, including cancer-targeting treatm

151 rstand the cancer resistance and move toward personalized medicine, it is essential to consider signa

152 f genome-wide association studies (GWAS) and personalized medicine, predicting the impact of single n

153 In the era of personalized medicine, until a more biologically based u

154 advantages in point-of-care diagnostics and personalized medicine.

155 py to further the clinical implementation of personalized medicine.

156 tanding of physiology and the development of personalized medicine.

157 ior to human trials, within the framework of personalized medicine.

158 aterial for clinical risk stratification and personalized medicine.

159 llenges privacy and data deidentification in personalized medicine.

160 nses in patients, thereby paving the way for personalized medicine.

161 gy technology, dentistry, drug delivery, and personalized medicine.

162 l-based therapies an attractive strategy for personalized medicine.

163 ct in tissue engineering, cancer therapy and personalized medicine.

164 populations, with immediate implications for personalized medicine.

165 ht us to the doorstep of widespread usage of personalized medicine.

166 e designed to facilitate cancer research and personalized medicine.

167 even more important from the perspective of personalized medicine.

168 rug resistance mechanisms for advancement of personalized medicine.

169 atient-specific cells for drug discovery and personalized medicine.

170 ed drug delivery), opening new dimensions in personalized medicine.

171 cular systems biology, clinical research and personalized medicine.

172 thy human proteome baseline is essential for personalized medicine.

173 ng of liver cancer biology and in developing personalized-medicine approaches for the disease.

174 peptides are a promising next generation of personalized medicines to reinstate biological harmony.

175 al diversity and enables an understanding of personalized microbiome function and dynamics.

176 The personalized model is created using flow data from four-

177 Model selection is used to make a personalized model selection for the individual and thei

178 We term this personalized model the cardiovascular avatar.

179 The extent to which personalized monitoring frequencies may be cost-effectiv

180 We compared the cost-effectiveness of the personalized monitoring strategies to fixed monitoring i

181 tic functions show great promise in terms of personalized nanomedicine for patient-specific diagnosis

182 notherapy and suggest a general strategy for personalized nanomedicine.

183 tIDS holds promise for high-efficacy personalized neuromodulations based on individual local

184 However, as compelling and intuitive as personalized nutrition might be in the current era in wh

185 sible, appropriately and objectively vetting personalized nutrition strategies is not trivial and req

186 Finally, we discuss the limitations of personalized nutrition studies, possible extensions of N

187 nonrisk carriers across different levels of personalized nutrition.A total of 683 participants (wome

188 arch that are meant to assess the utility of personalized nutritional strategies.

189 Personalized O2 pathway analysis could identify patients

190 ious therapeutic strategies, so as to enable personalized or precision therapy.

191 ost widely used techniques for this problem, personalized PageRank and heat kernel methods, operate i

192 the gradient is asymptotically equivalent to personalized PageRank for a specific choice of the PageR

193 vides a formal motivation for the success of personalized PageRank in seed set expansion and node ran

194 nodes from the querying results based on the personalized PageRank vector for the induced network tha

195 n, especially because of the advantages that personalized pharmaceutical treatments would offer.

196 his highlights the exceptional potential for personalized precision medicine.

197 eity is important for precision diagnostics, personalized predictions, and recruitment of relatively

198 prior offer history to provide accurate and personalized predictions.

199 The results of MeDALL will help integrate personalized, predictive, preventative, and participator

200 chanisms and translating this knowledge into personalized prevention and management strategies.

201 late this into better diagnoses and properly personalized prevention and treatment plans.

202 in different individuals provide targets for personalized (psycho)therapy.

203 than the existing approaches for evaluating personalized radiobiological effects in radiotherapy.

204 To determine the personalized rate of uveal melanoma-related metastasis o

205 The ARC families received personalized referrals to mental health care and check-i

206 n conclusion, the new strategy, called PRES (Personalized REgimen Selection), may significantly incre

207 on syndromes and can be leveraged to improve personalized risk assessment and develop novel intervent

208 Findings also indicate that personalized risk assessment and optimal treatment could

209 the Vdelta2(+) subset, involving a central, personalized role for the gammadelta TCR in directing a

210 global ASCVD risk has the potential to guide personalized SBP goals (eg, choosing a traditional goal

211 By using a high-throughput personalized screening approach, we identified neoantige

212 he importance of ensuring access to lifelong personalized screening, surveillance, and chronic diseas

213 data, sets a new reproducible benchmark for personalized seizure detection.

214 the feasibility and importance of generating personalized specificity profiles.

215 This information might be used in designing personalized strategies for population-based CRC screeni

216 and one that uses guided imagery to present personalized stress, alcohol, or neutral stimuli.

217 Personalized studies to uncover mechanisms leading to di

218 Nonetheless, in selected cases, personalized surgery-based multimodality treatments (MMT

219 The personalized system discriminated between light- and dee

220 h can help clinicians determine appropriate, personalized target IOPs for patients with OAG.

221 (IOP) levels to aid clinicians with setting personalized target IOPs.

222 Design of personalized targeted therapies involve modeling of pati

223 enomic characterization of tumors can inform personalized targeted therapies.

224 al neurodynamics can enhance the efficacy of personalized tES.SIGNIFICANCE STATEMENT This study demon

225 estrogen signaling and open new avenues for personalized therapeutic approaches targeting Src or MEK

226 nologic progression, and provide avenues for personalized therapeutic interventions and precision med

227 tual insights into RTT etiology that support personalized therapeutic interventions.

228 eptor repertoire, and direct the design of a personalized therapeutic.

229 The Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patient

230 lidated in the Airway Disease Endotyping for Personalized Therapeutics cohort.

231 disease models and designer cell samples for personalized therapeutics will require harnessing pheno-

232 sessment, towards providing a foundation for personalized therapeutics.

233 an essential step toward development of new personalized therapies and diagnostics.

234 to the development of precision medicine and personalized therapies for optimal therapeutic efficacy.

235 ding a novel noninvasive strategy to develop personalized therapies using neoantigen-reactive lymphoc

236 might provide immunotherapeutic targets for personalized therapies.

237 f the disease calls for rapid development of personalized therapies.

238 ections of nanotechnology-based targeted and personalized therapy are discussed.

239 of its pathways and mechanisms have enabled personalized therapy in NSCLC.

240 Personalized therapy is a major goal of modern oncology,

241 Signature-based subtyping may guide personalized therapy of PDAC in the context of biomarker

242 this review may offer guidance in regard to personalized therapy recommendations.

243 ion can usher in a new era of highly focused personalized therapy that may be particularly beneficial

244 ial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment an

245 etic diagnosis is important as it can enable personalized therapy with abatacept, a CTLA-4 mimetic, a

246 acts, which will inform patient care, enable personalized therapy, and enhance the efficacy of immuno

247 imes over in just a few years through better personalized therapy.

248 trials for the development of more effective personalized therapy.

249 a prerequisite for using widening options of personalized therapy.

250 ignant development and offer new targets for personalized therapy.

251 ower generation used in wearable devices and personalized thermo-regulation.

252 erical control machine for manufacturing the personalized titanium plates by 3D printing.

253 Our work suggests that personalized titanium plates can significantly improve t

254 dy represents the first-time effort in using personalized titanium plates for such surgery.

255 The personalized titanium plates were then used for fixation

256 The 3D models were used to design the personalized titanium plates.

257 membrane oxygenation reinforces the need for personalized titration of ventilation settings.

258 sease heterogeneity and to develop therapies personalized to a given individual (precision medicine).

259 d in order to provide cancer therapy that is personalized to the patient and his or her unique genome

260 as a serial, comprehensive, and potentially personalized tool to characterize metabolism after injur

261 hat it may ultimately be possible to develop personalized toxicology to determine interindividual sus

262 of RBC alloimmunization and may benefit from personalized transfusion protocols and/or targeted thera

263 n, as well as individual-level diagnosis and personalized treatment and prevention plans.

264 ortant step toward developing strategies for personalized treatment and, ultimately, prevention.

265 r targeting is important because it allows a personalized treatment approach (theranostic approach).

266 s in response to social conditions support a personalized treatment approach to cocaine addiction.

267 uently in a fashion that may one day lead to personalized treatment approaches in a many-faced diseas

268 the conduct of additional research to guide personalized treatment approaches in this setting.

269 One approach to improving the personalized treatment of cancer is to understand the ce

270 typing is crucial for precision medicine and personalized treatment of complex diseases.

271 aid in more accurate diagnosis and design of personalized treatment options.

272 this model to create a tool that recommends personalized treatment regimens.

273 Personalized treatment reversed the visual loss, illustr

274 Our study suggests that development of personalized treatment strategies for breast cancer pati

275 pathologic data may be a crucial step toward personalized treatment strategies for this disease.

276 d abscopal response and therefore may inform personalized treatment strategies in patients with metas

277 ges associated with disease activity, define personalized treatment strategies, and generally inform

278 tional characterization and translation into personalized treatment strategies.

279 ctivity index has the potential to provide a personalized treatment target to improve patient outcome

280 n be simply defined as the identification of personalized treatment that matches patient-specific cli

281 Here, to identify potential targets for personalized treatment, we perform integrative genome-wi

282 iate patient risk stratification, and prompt personalized treatment.

283 t predict altered immunity, thereby enabling personalized treatment.

284 sk assessment for ESRD, and pave the way for personalized treatment.

285 n for diagnosis, prognosis, and, eventually, personalized treatment.

286 cancer (EC) patients is important in a more personalized treatment.

287 work building on these findings will inform personalized treatment.

288 r of tumor signaling state that could aid in personalized treatment.

289 h a diagnostic target and a means of guiding personalized treatment.

290 nce to cancer therapies and provide patients personalized treatment.

291 used to help guide mechanistically informed, personalized treatments and support the strategy of usin

292 s way, we hope to achieve more effective and personalized treatments for CTCL.

293 nd will open an avenue in the development of personalized treatments.

294 in the clinic for diagnostic purposes or for personalized treatments.

295 t of molecular targets that could facilitate personalized treatments.

296 er to see when friends have been vaccinated (personalized vaccination campaigns) and when they get th

297 ther topological features could be used as a personalized variable for clinical staging and aphasia t

298 to vitamin D dose-response is important for personalized vitamin D treatment and cost-effective dise

299 multicenter trial to test whether a simple, personalized walking exercise program at home, managed b

300 eeded to determine the cost-effectiveness of personalized warfarin dosing.